Stamulumab, CAS 705287-60-1

Product Description: Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research[1][2].

Applications: Metabolism-protein/nucleotide metabolism

Formula: N/A

References: [1]P Singh, et al. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy. Clin Transl Sci. 2016 Dec;9(6):302-310./[2]Kathryn R Wagner, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008 May;63(5):561-71.

CAS Number: 705287-60-1

Molecular Weight: N/A

Compound Purity: 95.07

Research Area: Metabolic Disease

Solubility: H2O

Target: TGF-β Receptor

• Artikelnummer: MEXHY-P99588-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99588-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated